 |
Inhibitors of the Uric Acid Transporter URAT1 Require URAT1 Phenylalanine 365 for High Affinity Interaction |
|
Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given in Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Preliminary Results from the Randomized, Blinded, Placebo-Controlled, Phase 2b Extension Study |
|
Pharmacokinetics, Efficacy and Safety of Lesinurad, A Novel URAT1 Inhibitor, in Individuals with Mild to Moderate Renal Impairment |
|
Lesinurad (RDEA594), A Investigational Uricosuric Agent for Hyperuricemia and Gout, Blocks OAT4 Transport, Mechanism of Hydrochlorothiazide-Dependent Hyperuricemia |
|
Lesinurad (RDEA594), A Novel Uricosuric Agent, in Combination with Febuxostat Shows Significant Additive Urate Lowering Effects in Gout Patients with 100% Response Achieved for All Combination Dose Regimens |
|
A RDEA594, A Novel Uricosuric Agent, Shows Significant Additive Activity in Combination with Allopurinol in Gout Patients |
|
RDEA594, A Novel URAT1 Inhibitor, Shows Significant Additive Urate Lowering Effects in Combination with Febuxostat in Both Healthy Subjects and Gout Patients |
|
Pharmacokinetics and Serum Urate Lowering Effect of RDEA594, A Novel URAT1 Inhibitor, In Gout Patients and Subjects with Varying Degrees of Renal Impairment |
|
A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of BAY 86-9766 (RDEA119), a MEK Inhibitor, in Advanced Cancer Patients |
|
Efficacy and Safety of RDEA594, a Novel Uricosuric Agent, as Combination Therapy with Allopurinol in Gout Patients: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Experience |
 |
RDEA594, a Novel Uricosuric Agent, Shows Impressive Reductions in Serum Urate Levels as a Monotherapy and Substantial Additive Activity in Combination with Febuxostat in Normal Healthy Volunteers |
 |
RDEA594, a Novel Uricosuric Agent, Significantly Reduced Serum Urate Levels and Was Well Tolerated in a Phase 2a Pilot Study in Hyperuricemic Gout Patients |
 |
Evaluation of Drug-Drug Interaction Potential Between RDEA594, Allopurinol and Febuxostat in Preclinical Species |
 |
Safety, Pharmacokinetics, and Serum Uric Acid Lowering Effect of RDEA594, A Novel, Uricosuric Agent, In Healthy Volunteers |
 |
RDEA594: A Potent URAT1 Inhibitor Without Affecting Other Important Renal Transporters, OAT1 and OAT3 |
 |
Selective MEK1/2 Inhibitors RDEA436 and RDEA119 Exhibit Anti-Inflammatory Efficacy in Mono and Combination Therapy with Methotrexate in Pristane-Induced Arthritis in Rats |
 |
The Selective MEK Inhibitor RDEA119: Synergy with Multiple Classes of Anti-Cancer Agents |
 |
In Vitro Resistance Selection Study and Favorable PK Properties of RDEA427, a New NNRTI |
 |
RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806 |
 |
The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial |
 |
Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTI’s |
 |
RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer |
 |
RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice |
 |
Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor |
 |
Biosynthesis of Oxidative and Conjugated Metabolites of VRX-480773 and Identification of their Structures by LC-MS/MS and NMR |
 |
Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, a Novel Prodrug for the Potential Treatment of Hyperuricemia |
 |
Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Pro-drug, RDEA806 |
 |
RDEA119, A Selective MEK RDEA119, A Selective MEK 1/2 Inhibitor Ameliorates Experimental Arthritis |
 |
RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties |
 |
RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies |
 |
A Novel NNRTI Class with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses |
 |
RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity Against NNRTI-Resistant Viruses |
 |
An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins |
 |
RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer |
 |
The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials |
 |
RDEA806, a Potent NNRTI with a High Genetic Barrier to Resistance |
 |
Safety and Pharmacokinetics of Ascending Single Oral Doses of RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers |
 |
RDEA806, A Potent Non-Nucleoside Reverse Transcriptase Inhibitor with Less Potential for Drug-Drug Interactions |
